This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Velcade
Generic Name
Bortezomib D-mannitol
DrugBank Accession Number
DB16741
Background

Not Available

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 530.39
Monoisotopic: 530.254794
Chemical Formula
C25H35BN4O8
Synonyms
  • Bortezomib D-mannitol ester
  • Bortezomib D-mannitol symmetrical ester
  • Bortezomib mannitol boronic ester

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bortezomib D-mannitol.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bortezomib D-mannitol.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bortezomib D-mannitol.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Bortezomib D-mannitol.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Bortezomibprodrug69G8BD63PP179324-69-7GXJABQQUPOEUTA-RDJZCZTQSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Act BortezomibPowder, for solution3.5 mg / vialIntravenous; SubcutaneousTEVA Canada Limited2015-11-17Not applicableCanada flag
BortezomibPowder, for solution3.5 mg / vialIntravenous; SubcutaneousApotex Corporation2019-03-25Not applicableCanada flag
Bortezomib for InjectionPowder, for solution3.5 mg / vialIntravenous; SubcutaneousDr Reddy's Laboratories2017-03-21Not applicableCanada flag
Bortezomib for InjectionPowder, for solution3.5 mg / vialIntravenous; SubcutaneousAuro Pharma IncNot applicableNot applicableCanada flag
Bortezomib for InjectionPowder, for solution3.5 mg / vialIntravenous; SubcutaneousMarcan Pharmaceuticals Inc2020-05-19Not applicableCanada flag
Bortezomib for InjectionPowder, for solution3.5 mg / vialIntravenous; SubcutaneousPfizer Canada UlcNot applicableNot applicableCanada flag
Bortezomib for InjectionPowder, for solution3.5 mg / vialIntravenous; SubcutaneousJuno Pharmaceuticals Corp.Not applicableNot applicableCanada flag
Bortezomib for InjectionPowder, for solution3.5 mg / vialIntravenous; SubcutaneousTEVA Canada Limited2015-01-06Not applicableCanada flag
Bortezomib for InjectionPowder, for solution2.5 mg / vialIntravenous; SubcutaneousJuno Pharmaceuticals Corp.2020-10-05Not applicableCanada flag
Bortezomib for InjectionPowder, for solution3 mg / vialIntravenous; SubcutaneousPfizer Canada UlcNot applicableNot applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
PMS-bortezomibPowder, for solution3.5 mg / vialIntravenous; SubcutaneousPharmascience Inc2018-06-05Not applicableCanada flag
Taro-bortezomibPowder, for solution2.5 mg / vialIntravenous; SubcutaneousTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada flag
Taro-bortezomibPowder, for solution3.5 mg / vialIntravenous; SubcutaneousTaro Pharmaceuticals, Inc.2021-04-12Not applicableCanada flag
Taro-bortezomibPowder, for solution1 mg / vialIntravenous; SubcutaneousTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
P2AWN9VSQ6
CAS number
444576-08-3
InChI Key
QDMRNLRJDHCHLB-DNNBANOASA-N
InChI
InChI=1S/C25H35BN4O8/c1-15(2)10-21(26-37-22(19(33)13-31)23(38-26)20(34)14-32)30-24(35)17(11-16-6-4-3-5-7-16)29-25(36)18-12-27-8-9-28-18/h3-9,12,15,17,19-23,31-34H,10-11,13-14H2,1-2H3,(H,29,36)(H,30,35)/t17-,19+,20+,21-,22+,23+/m0/s1
IUPAC Name
(2S)-N-[(1R)-1-[(4R,5R)-4,5-bis[(1R)-1,2-dihydroxyethyl]-1,3,2-dioxaborolan-2-yl]-3-methylbutyl]-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamide
SMILES
[H][C@@]1(OB(O[C@]1([H])[C@H](O)CO)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)[C@H](O)CO

References

General References
Not Available
ChemSpider
64854571

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionKidney Transplantation1
4CompletedTreatmentHLA Sensitization1
4CompletedTreatmentMultiple Myeloma (MM)1
4RecruitingTreatmentHematological Neoplasms1
4RecruitingTreatmentMultiple Myeloma (MM)1
4TerminatedTreatmentMultiple Myeloma (MM)1
4Unknown StatusTreatmentMultiple Myeloma (MM)1
4Unknown StatusTreatmentWaldenström's Macroglobulinemia (WM)1
4WithdrawnTreatmentHematuria / Lupus Nephritis / Proteinuria1
3Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Granulocytic Sarcoma / Leukaemia cutis / Myeloid Neoplasm1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionIntravenous1 mg / vial
Powder, for solutionIntravenous; Subcutaneous1 mg / vial
Powder, for solutionIntravenous; Subcutaneous2.5 mg / vial
Powder, for solutionIntravenous; Subcutaneous3 mg / vial
Powder, for solutionIntravenous; Subcutaneous3.5 mg / vial
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.639 mg/mLALOGPS
logP-0.21ALOGPS
logP0.12ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)12.75ChemAxon
pKa (Strongest Basic)-0.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area183.36 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity130.22 m3·mol-1ChemAxon
Polarizability55.93 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at November 27, 2021 17:13 / Updated at June 28, 2022 06:16